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Despite the many therapeutic options available today for the treatment of hypertension, a sizable number of patients still remain
resistant to treatment. The prevalence of resistant hypertension in the general population under optimal conditions is about
3–5%. Although several factors and conditions can be identiﬁed and corrected a percentage of hypertensive patients remain
with unacceptably high blood pressure levels. The high prevalence of hypertension in the general population renders this small
percentage signiﬁcant, in terms of actual patient numbers. This special issue of the journal expoars a whole spectrum of topics
related to resistant hypertension: several articles address pathophysiolog and secondary causes of resistant hypertension and
modernapproachestotherapy. Ofinterestisthereferance tothenewerinterventionalapproaches,thatis,Baroreceptorstimulation
therapy and catheter based sympathetic renal denervation.
1.Approaches to Diagnosis and Treatmentof
Difﬁcult-to-TreatorResistantHypertension
Resistant or diﬃcult-to-control hypertension is becoming
an increase burden in our society. Although with the many
medical approaches available to us we can currently control
the majority of patients with hypertension, a sizable number
still remain resistant to treatment. The prevalence of re-
sistant hypertension in the general population is diﬃcult
to determine accurately, but depending on the population
and the center reporting it ranges from 5% to 30% [1, 2].
In specialized clinics utilizing optimal medical regimens the
prevalence is closer to 3–5%. Although several factors and
conditions can be identiﬁed and corrected (poor patient
adherence, physician inertia, inappropriate drug combina-
tions or inadequate dosing, drug-induced hypertension, and
secondary causes), the fact is that a percentage of hyperten-
sive patients remain with unacceptably high blood pressure
levels. The high prevalence of hypertension in the general
population renders this small percentage signiﬁcant, in
terms of actual patient numbers. The above, combined with
several limitations in drug therapy (patient adherence, pol-
ypharmacy, and drug adverse eﬀects), create the need for
other therapeutic options, beyond existing antihypertensive
medications, setting the basis for interventional approaches
[3–5]. Recently two new innovative, still experimental inter-
ventional approaches to treat “resistant or diﬃcult-to-con-
trol hypertension” have been explored: the baroreceptor
stimulation with the Rheos device and sympathetic renal
denervation using radiofrequency ablation techniques.
2.Pathophysiology
This special issue of the journal includedpapers covering the
whole spectrum of issues related to “resistant or Diﬃcult-to-
treat hypertension.”
In the ﬁrst paper C. Tsiouﬁs and coworkers reviewed the
pathophysiology of resistant hypertension and the role of
sympathetic nervous system. They emphasize that obesity,
obstructive sleep apnea, and aldosterone are predisposing
factors, but increased sympathetic nervous system activity2 International Journal of Hypertension
is paramount prevailing future of all these underlying con-
ditions, supporting its crucial role in the development of
treatment resistance. They alsopoint outthatcurrentclinical
and experimental data indicate an impact of several factors
on SNS activation, namely, insulin resistance, adipokines,
endothelial dysfunction, cyclic intermittent hypoxaemia,
aldosterone eﬀects on central nervous system, chemorecep-
tors, and baroreceptors dysregulation. V. M. Campese et al.,
examine the inﬂuence of sympathetic nervous system and
the role of the kidney in the development of resistant hyper-
tension. They point out not only that several factors have
been implicated in the pathogenesis of hypertension such
as sodium and water retention, total body volume expan-
sion, and hyperactivity of the renin-angiotensin aldosterone
system (RAAS) but also that increasing evidence suggests
that aﬀerent impulses from the injured kidney may increase
sympathetic nervous system activity in areas of the brain
involved in noradrenergic regulation of blood pressure
and contribute to the development and maintenance of
hypertension associated with kidney disease. Recognition of
thisimportant pathogenicfactor suggeststhatantiadrenergic
drugs or therapies should be an essential component to the
managementofhypertensioninpatientswithkidneydisease,
particularly those who are resistant to other modalities of
therapy.
3.SecondaryCausesofHypertensionas
a CauseofResistance
M. C. Acelajado and D. A. Calhoun examine the role
of primary hyperaldosteronism in the development of drug-
resistant hypertension. They point out that the incidence
of primary aldosteronism in patients with drug resistant
hypertension is 14% to 23%, which is much higher than
in the general hypertensive population. These patients have
increased cardiovascular risk, as shown by higher rates of
stroke, myocardial infarction, and arrhythmias compared to
hypertensive individuals without primary hyperaldostero-
nism. Furthermore, resistant hypertension is associated with
adverse cardiovascular outcomes. Addition of aldosterone
antagonists to the antihypertensive regimen in patients with
resistant hypertension produces a profound BP-lowering
eﬀect, and this eﬀect is seen in patients with or without
biochemical evidence of PA, highlighting the role of relative
aldosterone excess in driving treatment resistance in this
group of patients. S. Kshatriya et al. in an intriguing paper,
examine theregulatory roleofleptininobesityhypertension.
Leptin is a 16-kDa-peptide hormone that is primarily syn-
thesized and secreted by adipose tissue. One of the major
actions of this hormone is the control of energy balance
by binding to receptors in the hypothalamus, leading to
reduction in food intake, elevation in temperature, and
energyexpenditure.Inaddition,increasing evidencesuggests
that leptin, through both direct and indirect mechanisms,
may play an important role in cardiovascular and renal
regulation. While the relevance of endogenous leptin needs
further clariﬁcation, it appears to function as a pressure
and volume-regulating factor under conditions of health.
However, in abnormal situations characterized by chronic
hyperleptinemia such as obesity, it may function patho-
physiologically for the development of hypertension and
possibly also for direct renal, vascular, and cardiac damage.
Z. Khawaja and C. S. Wilcox examine the role of the kidney
in thedevelopmentof resistant hypertension. They point out
that the kidneyplaysacritical role in long-termregulation of
blood pressure. Blunted pressure natriuresis, with resultant
increase in extracellular ﬂuid volume, is an important
cause of resistant hypertension. Activation of the renin-
angiotensin-aldosterone system, increased renal sympathetic
nervous system activity, and increased sodium reabsorp-
tion are important renal mechanisms. Successful treatment
requires identiﬁcation and reversal of lifestyle factors or
drugs contributing to treatment resistance, diagnosis, and
appropriate treatment of secondary causes of hypertension,
use of eﬀective multidrug regimens, and optimization of
diuretic therapy. Since inappropriate renal salt retention
underliesmostcasesofdrug-resistanthypertension, thether-
apeutic focus should be on improving salt depleting therapy
by assessing and, if necessary, reducing dietary salt intake,
optimizing diuretic therapy, and adding a mineralocorticoid
antagonist if there are no contraindications.
A. Makris et al. addressed the issue of workup and treat-
ment of patients with resistant hypertension. Evaluation of
patients with resistant hypertension should begin by con-
ﬁrming that patients have true resistant hypertension. White
coat hypertension, suboptimal blood pressure measurement
technique, poor adherence to prescribed medication, sub-
optimal dosing of antihypertensive agents or inappropriate
combinations, the white coat eﬀect, and clinical inertia
should be excluded. Management includes lifestyle and di-
etary modiﬁcation, elimination of medications contributing
to resistance, and evaluation of potential secondary causes of
hypertension. Pharmacological treatment should be tailored
to the patient’s proﬁle and focus on the causative pathway
of resistance. D. Syrseloudis et al. address the crucial role
of ambulatory blood pressure monitoring in the diagnosis
and treatment of patients with resistant hypertension. The
identiﬁcation of white coat hypertension and masked hyper-
tension is of great importance in the clinical management
of such patients. Moreover, the various ABPM components
such as average BP values, circadian BP variability patterns,
and ambulatory blood pressure-derived indices, such as
ambulatory arterial stiﬀness index, add signiﬁcantly to the
risk stratiﬁcation ofresistant hypertension. Obstructive sleep
apnea is a frequent cause of resistant hypertension, and C.
Thomopoulos and coworkers have done a wonderful job
in exploring the interaction between the two entities and
implications for successful treatment. Enhanced target organ
damage and cardiovascular morbidity represent common
issues observed in both resistant hypertension and obstruc-
tive sleep apnea. Common pathophysiological features and
risk factors justify their coexistence, especially in individuals
with increased upper-body adiposity. Impaired sodium
handling, sympathetic activation, accelerated arterial stiﬀ-
ening, and impaired cardiorenal hemodynamics contribute
to drug-resistant hypertension development in obstructive
sleep apnea. Eﬀective CPAP therapy qualiﬁes as an eﬀectiveInternational Journal of Hypertension 3
“add-on”treatment totheunderlying antihypertensive phar-
macological therapy, and emerging evidence underlines the
favorable eﬀect of mineralocorticoid antagonists on both
resistant hypertension and obstructive sleep apnea treat-
ment. Furthermore, A. Moraitis and C. Stratakis address ad-
renocortical causes if resistant hypertension.
4.Approachesto Treatment
C. Faselis and coworkers explored Common secondary
causes of resistant hypertension and rational for treatment.
They point out several secondary causes and a long list
of factors contributing to resistant hypertension such as
poor patient adherence, physician inertia, inadequate doses
or inappropriate combinations of antihypertensive drugs,
excess alcohol intake, and volume overload. They correctly
point out that management of patients with resistant hyper-
tension requires a combination of clinical acumen and com-
m o ns e n s e .A ne x t e n s i v ew o r k u po fa l lp a t i e n t sw i t hu n c o n -
trolledhypertension isscientiﬁcally unsound,very costlyand
requiresimmense human andtechnical resources. Therefore,
they recommend practicing evidence-based medicine. The
eﬀectivemanagement ofpatients with resistant hypertension
requires an appropriate combination of physiology and
pharmacology,takingintoaccounttheuniquecharacteristics
of each case in order to tailor the therapeutic approach
to the individual patient. They indicate that there are at
least 14 endocrine disorders in which hypertension may
be the initial clinical presentation. An accurate diagnosis
of endocrine hypertension provides the clinician with a
unique treatment opportunity, that is, to render a surgical
cure or to achieve a dramatic response with pharmacologic
therapy. In this paper the authors review mostly diﬀerent
aspects of primary hyperaldosteronism, which represents
the most common cause of endocrine resistant hyperten-
sion.
In the following paper, M. Doumas et al. address poten-
tial beneﬁts from the treatment and control of resistant
hypertension. They point out that several factors have
been identiﬁed as contributors to resistant hypertension:
poor patient adherence, physician inertia, inadequate doses
or inappropriate combinations of antihypertensive drugs,
secondary forms of hypertension, drug-induced hyperten-
sion, excess alcohol intake, and volume overload. Life-style
modiﬁcations including salt restriction are very important
in these patients. Addressing some of the comorbid con-
ditions, such as sleep apnea, primary aldosteronism, or
addition of adjunct therapies such as spironolactone, can
achieve blood pressure control. However, many patients
remain uncontrolled despite the use of four, ﬁve, or six
antihypertensive drugs, especially in everyday clinical prac-
tice, outside the “sterile” environment of clinical trials.
It is surprising to realize that, although hypertension is
among the most studied diseases, resistant hypertension
which denotes the most severe, high-risk, and probably
more scientiﬁcally interesting subgroup remains so much
understudied. Unfortunately, data regarding the natural
history of resistant hypertension is limited. Furthermore,
the beneﬁts of controlling blood pressure in patients with
resistant hypertension are vaguely clariﬁed, and it seems that
they will continue to remain as such, since it is unethical to
performarandomizedstudywithacontrolgroupofresistant
hypertensives that will remain untreated. Since direct data
is not available, only clinically meaningful assumptions can
be made based on indirect information and using common
sense. Therefore, for the purpose of this review, they use data
from the past (before the era of antihypertensive therapy),
data from clinical studies involving patients with severe or
malignant hypertension, data from small clinical studies in
patients with resistant hypertension, and from subgroups of
patients included in large clinical trials.
In the next paper, P. M. Jansen et al. indicate that
the long-term eﬃcacy of aldosterone-receptor antagonists
(ARAs) as add-on treatment in uncontrolled hypertension
has not yet been elucidated. They present data from 123
patients (21 with primary aldosteronism, 102 with essen-
tial hypertension) with diﬃcult-to-treat hypertension who
received an aldosterone receptor antagonist over a four-
year period. Results suggest a profound and sustained blood
pressure reduction over a median follow-up period of 25
months.
In the last two papers, V. Papademetriou and coworkers
review the role of devices and interventions in the man-
agement of patients with resistant hypertension. The ﬁrst
device to be used in the treatment of resistant hypertension
was the Rheos baroreceptor stimulator. Baroreceptor stim-
ulation is achieved through this pulse generator implanted
subcutaneously(muchlikeapacemaker),which isconnected
to two leads rubbed around the carotid bulbs. The two
early studies that include about 110 patients demonstrated
signiﬁcant eﬃcacy of the device with up to 30/18mmHg
reduction in blood pressure, which can be maintained long
term. A larger pivotal study, which included a blinded
arm, recently completed recruitment of 300 patients. The
study is still in progress, and results have not been an-
nounced.
Selective renal sympathetic denervation is an even more
ambitious approach aiming to possibly cure hypertension.
This new interventional approach provides the hope of an
easy, long-term blood pressure control without signiﬁcant
adverse events. Using a specially designed catheter, this
technique aims to interrupt the sympathetic ﬁbers that
interact with the kidney and kidney function. More impor-
tantly this technique also interrupts the eﬀerent ﬁbers
from the kidney to the brain that may control peripheral
vascular tone and peripheral resistance. The net eﬀect of
the sympathetic ﬁber network that runs along the renal
arteries results in signiﬁcant blood pressure reduction. A
limited number of cases have been reported, but much
larger studies are underway trying to evaluate the role of
this new and innovative approach to treat resistant hyper-
tension.
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